Roche's Lunsumio clears Phase 3 hurdle, paving way for broader label in indolent lymphoma

Roche announced that its T cell engager Lunsumio successfully met the primary endpoints in a Phase 3 study of a slow growing blood cancer.

The trial, conducted in patients with indolent lymphoma, showed sufficient efficacy and safety to satisfy regulators and open the possibility of full approval.

With the positive data, Roche plans to seek an expanded label that would cover a broader patient population beyond the current indication.

The result is expected to strengthen Roche's oncology pipeline and could have material impact on its market position.